Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 13, 2026Frontiers in MicrobiologyOpen Access

Recombinant RBD-based subunit vaccines incorporating high-frequency mutation sites elicit cross-immunity and robust protection against SARS-CoV-2

View Full Paper
Ask AI
Bookmark
Share

Authors

ZRZhiguang RenXLXiawei LiuWSWeiyang Sun

Discussion

Loading...

Member takes

Overview

Randomized trial shows effective cross-immunity and protection in developing SARS-CoV-2 vaccines, highlighting their potential for future pandemics.

Key Points

  • The research aims to develop recombinant RBD-based subunit vaccines that provide broad-spectrum immunity against SARS-CoV-2 variants.
  • Expressed three tandem-repeat dimeric recombinant RBD proteins using an insect-baculovirus system.
  • Conducted immunogenicity assessments and attack protection tests to evaluate vaccine efficacy.
  • The vaccines elicited varying degrees of cross-immunity response against SARS-CoV-2 variants, showing significant protective effects.
  • Impact on immune evasion was assessed, indicating strong potential for effective long-term protection against emerging strains.

Cite This Study

Ren et al. (2026) studied this question.

synapsesocial.com/papers/6a2cf2a9faef96ed7f055785https://doi.org/10.3389/fmicb.2026.1806270
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Preclinical evaluation of a COVID-19 vaccine candidate based on a recombinant RBD fusion heterodimer of SARS-CoV-22023 · 28 citations
  2. 2Preclinical assessment of a recombinant RBD-Fc fusion protein as SARS-CoV-2 candidate vaccine2024 · 10 citations
  3. 3Broad‐spectrum coronavirus neutralization induced by hetero RBD‐Fc protein vaccine2024 · 2 citations
  4. 4Broad-spectrum coronavirus neutralization induced by hetero RBD-Fc protein vaccine2024 · 1 citations
  5. 5Development of Glycan-masked SARS-CoV-2 RBD vaccines against SARS-related coronaviruses2024 · 5 citations